Patient profiling for treatment toxicity: Potential use of clinical and genomic factors

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 37-41

  Armstrong, Terri S ^a,b   Gilbert, Mark R ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Genomics; Toxicity

Indexed keywords

BILIRUBIN; IRINOTECAN; MERCAPTOPURINE; MITOMYCIN C; TEMOZOLOMIDE; URIDINE DIPHOSPHATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DIARRHEA; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GILBERT DISEASE; GLIOBLASTOMA; GSTP1 GENE; HUMAN; MARKER GENE; MGMT GENE; NEUTROPENIA; NQO1 GENE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TPMT GENE; TREATMENT PLANNING; URIDINE DIPHOSPHATE GLUCORONOSYLTRANSFERASE 1A1 GENE;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; GENOME, HUMAN; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 79551534853     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0141-0     Document Type: Article

References (25)

1. DW Nebert G Zhang ES Vesell 2008 From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions Drug Metab Rev 40 187 224 1:CAS:528:DC%2BD1cXnsVyqs7Y%3D 10.1080/03602530801952864 18464043 (Pubitemid 352000946)
2. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55. This is a comprehensive review of pharmacogenetics related to chemotherapy.
3. Feero WG, Guttmacher AE, Collins FS. Genomic medicine - an updated primer. N Engl J Med 2010;362:2001-11. This article provides an up-to-date review of the current state of the science in relation to genomics.
4. H Varmus 2002 Getting ready for gene-based medicine N Engl J Med 347 1526 7 10.1056/NEJMe020119 12421898 (Pubitemid 35257595)
5. ES Lander LM Linton B Birren, et al. 2001 Initial sequencing and analysis of the human genome Nature 409 860 921 1:CAS:528:DC%2BD3MXhsFCjtLc%3D 10.1038/35057062 11237011 (Pubitemid 32165345)
6. UA Meyer 2004 Pharmacogenetics - five decades of therapeutic lessons from genetic diversity Nat Rev Genet 5 669 76 1:CAS:528:DC%2BD2cXnt12nt78%3D 10.1038/nrg1428 15372089 (Pubitemid 39150124)
7. • Huang RS, Dolan ME. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics;11:471-4. This article provides a framework for the development and validation of SNPs associated with toxicity and application to the clinical setting.
8. A haplotype map of the human genome. Nature 2005;437:1299-320.
9. SN Iyer MC Chappell KB Brosnihan CM Ferrario 1998 Role of AT1 and AT2 receptors in the plasma clearance of angiotensin II J Cardiovasc Pharmacol 31 464 9 1:CAS:528:DyaK1cXhs1ansbo%3D 10.1097/00005344-199803000-00019 9514193 (Pubitemid 28103628)
10. JM Hoskins RM Goldberg P Qu JG Ibrahim HL McLeod 2007 UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99 1290 5 1:CAS:528:DC%2BD2sXhtVWqtbnI 10.1093/jnci/djm115 17728214 (Pubitemid 47394168)
11. ML Rothenberg 1998 Efficacy and toxicity of irinotecan in patients with colorectal cancer Semin Oncol 25 39 46 1:CAS:528:DyaK1cXntVOgu7w%3D 9786315
12. LE Carlini NJ Meropol J Bever, et al. 2005 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan Clin Cancer Res 11 1226 36 1:CAS:528:DC%2BD2MXht1yntLk%3D 15709193
13. L Lennard JS Lilleyman J Van Loon RM Weinshilboum 1990 Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia Lancet 336 225 9 1:STN:280:DyaK3czisFyqsQ%3D%3D 10.1016/0140-6736(90)91745-V 1973780 (Pubitemid 20229068)
14. M Stanulla E Schaeffeler T Flohr, et al. 2005 Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia JAMA 293 1485 9 1:CAS:528: DC%2BD2MXis1Crsbk%3D 10.1001/jama.293.12.1485 15784872 (Pubitemid 40393293)
15. Y Hasegawa T Sarashina M Ando, et al. 2004 Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay Clin Chem 50 1479 80 1:CAS:528:DC%2BD2cXmtFKnsLo%3D 10.1373/clinchem.2004.034694 15277366 (Pubitemid 38970674)
16. L Iyer CD King PF Whitington, et al. 1998 Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 847 54 1:CAS:528:DyaK1cXht1Wrtrc%3D 10.1172/JCI915 9466980
17. MJ Ratain 2006 From bedside to bench to bedside to clinical practice: an odyssey with irinotecan Clin Cancer Res 12 1658 60 10.1158/1078-0432.CCR-06-0159 16551845
18. • Lambert LA, Armstrong TS, Lee JJ, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 2009;16:2181-7. This evaluation combines multiple clinical factors and SNPs associated with treatment toxicity.
19. G Milano MC Etienne E Cassuto-Viguier, et al. 1992 Influence of sex and age on fluorouracil clearance J Clin Oncol 10 1171 5 1:STN:280: DyaK38zgtVChsA%3D%3D 1607921
20. RE Port B Daniel RW Ding R Herrmann 1991 Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance Oncology 48 277 81 1:STN:280:DyaK3MzmslChsw%3D%3D 10.1159/000226942 1891168
21. K Chansky J Benedetti JS Macdonald 2005 Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma Cancer 103 1165 71 1:CAS:528:DC%2BD2MXivFWgsL8%3D 10.1002/cncr.20878 15693031 (Pubitemid 40328086)
22. JA Sloan RM Goldberg DJ Sargent, et al. 2002 Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer J Clin Oncol 20 1491 8 1:CAS:528:DC%2BD38XivFeisbc%3D 10.1200/JCO.20.6.1491 11896096 (Pubitemid 34260527)
23. JL Yen HL McLeod 2007 Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43 1011 6 10.1016/j.ejca.2007.01.030 17350823 (Pubitemid 46483039)
24. JA Meyerhardt A Kwok MJ Ratain JP McGovren CS Fuchs 2004 Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer J Clin Oncol 22 1439 46 1:CAS:528:DC%2BD2cXpt1yjuro%3D 10.1200/JCO.2004.10.043 15084617 (Pubitemid 41103626)
25. TS Armstrong Y Cao ME Scheurer, et al. 2009 Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors Neuro Oncol 11 825 32 1:CAS:528:DC%2BC3cXotVOrtw%3D%3D 10.1215/15228517-2008-120 19179423